{"id":"paroxetine-lithium","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Tremor"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"10-15","effect":"Polyuria/polydipsia"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Thyroid dysfunction"}]},"_chembl":{"chemblId":"CHEMBL6067650","moleculeType":"Small molecule","molecularWeight":"749.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake at the presynaptic membrane. Lithium acts as a mood stabilizer by inhibiting inositol monophosphatase and affecting intracellular signaling cascades, particularly protein kinase C and glycogen synthase kinase-3 pathways. The combination is used to augment antidepressant efficacy and provide mood stabilization in treatment-resistant depression and bipolar disorder.","oneSentence":"Paroxetine inhibits serotonin reuptake while lithium modulates intracellular signaling and mood stabilization, together enhancing antidepressant and mood-stabilizing effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:49.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder, particularly treatment-resistant depression"},{"name":"Bipolar disorder depression"}]},"trialDetails":[{"nctId":"NCT00581009","phase":"PHASE1, PHASE2","title":"The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2001-05-30","conditions":"Major Depressive Disorder, Bipolar Disorder","enrollment":49},{"nctId":"NCT01416220","phase":"PHASE4","title":"Lithium Versus Paroxetine in Major Depression","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT04218981","phase":"NA","title":"Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-01-15","conditions":"Common Mental Disorder","enrollment":200},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT00400088","phase":"PHASE3","title":"Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide","status":"TERMINATED","sponsor":"Nova Scotia Health Authority","startDate":"2007-06","conditions":"Major Depressive Disorder","enrollment":2},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT00563992","phase":"PHASE1","title":"Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2001-01","conditions":"Bipolar Disorder","enrollment":98},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT00012558","phase":"NA","title":"Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1998-09","conditions":"Bipolar Disorder","enrollment":5000},{"nctId":"NCT00177567","phase":"PHASE4","title":"Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-07","conditions":"Bipolar Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["seroxat, lithan"],"phase":"marketed","status":"active","brandName":"Paroxetine+Lithium","genericName":"Paroxetine+Lithium","companyName":"Ministry of Health & Welfare, Korea","companyId":"ministry-of-health-welfare-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paroxetine inhibits serotonin reuptake while lithium modulates intracellular signaling and neurotransmitter activity, together enhancing serotonergic neurotransmission for mood stabilization. Used for Major depressive disorder, Bipolar disorder (depression phase), Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}